Yahoo
NYSE - Delayed Quote USD

Dr. Reddy's Laboratories Limited (RDY)

14.17 +0.06 (+0.43%)
At close: 4:00:02 PM EDT
14.17 0.00 (0.00%)
After hours: 5:21:51 PM EDT
Trade RDY on Coinbase
Chart Range Bar
Loading chart for RDY

What's happening with RDY?

49m ago
Powered by Yahoo Scout

Dr. Reddy’s Laboratories reported fiscal Q2 2027 revenue of $905 millionand EPS of $0.12 per ADS, both below estimates. Lower North American lenalidomide sales offset double-digit growth in the underlying business, while semaglutide supply remains a near-term catalyst. The company expects semaglutide supplies to resume in November 2026.

Powered by Yahoo Scout
  • Previous Close 14.11
  • Open 14.20
  • Bid 13.90 x 380000
  • Ask 14.24 x 420000
  • Day's Range 14.15 - 14.28
  • 52 Week Range 11.36 - 15.67
  • Volume 1,814,273
  • Avg. Volume 2,934,028
  • Market Cap (intraday) 11.805B
  • Beta (5Y Monthly) 0.25
  • PE Ratio (TTM) 39.36
  • EPS (TTM) 0.36
  • Earnings Date (est.) Jan 21, 2027
  • Forward Dividend & Yield 0.08 (0.59%)
  • 1y Target Est 14.31
  • Morningstar Rating Rating available with Stock Picks access

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. The company operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment. Its Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids with the customer requirements. Its Others segment engages in developing therapies in the fields of oncology and inflammation; and research, development, and commercialization of differentiated formulations. The company offers its products for various therapeutic categories, including gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology, vaccines, vitamins and minerals, and pain management. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.

www.drreddys.com

27,527

Full Time Employees

March 31

Fiscal Year Ends

Healthcare

Sector

Recent News

View More

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is S&P BSE SENSEX (^BSESN) .

YTD Return

RDY
1.50%
S&P BSE SENSEX (^BSESN)
12.63%

1-Year Return

RDY
6.42%
S&P BSE SENSEX (^BSESN)
11.78%

3-Year Return

RDY
11.02%
S&P BSE SENSEX (^BSESN)
16.14%

5-Year Return

RDY
21.04%
S&P BSE SENSEX (^BSESN)
25.55%

Earnings Trends

View More

Earnings Per Share

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY27
Revenue 86.71B
Earnings 9.25B
Profit Margin 10.67%

Q3

FY26

Q4

FY26

Q1

FY27

Q2

FY27

0
20B
40B
60B
80B
4.0%
6.0%
8.0%
10.0%
12.0%

Analyst Insights

View More

Analyst Price Targets

12.50 Low
14.31 Average
14.17 Current
15.70 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 9/29/2026
Analyst Citigroup
Rating Action Upgrade
Rating Buy
Price Action Raises
Price Target 1040 -> 1450

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    8.48%

  • Return on Assets (ttm)

    3.37%

  • Return on Equity (ttm)

    7.34%

  • Revenue (ttm)

    329.84B

  • Net Income Avi to Common (ttm)

    27.99B

  • Diluted EPS (ttm)

    0.36

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    76.24B

  • Total Debt/Equity (mrq)

    18.57%

  • Levered Free Cash Flow (ttm)

    -6.59B

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: